Use of biomarkers in the discovery of novel anti-schizophrenia drugs

Drug Discovery Today

Volumn 15, Issue 3-4, 2010, Pages 137-141

  Mikkelsen, Jens D ^a,b   Thomsen, Morten S ^a,b   Hansen, Henrik H ^b   Lichota, Jacek ^c  

^a Mental Health Services CPH   (Denmark)

^b NEUROSEARCH A S   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; BIOLOGICAL MARKER; BUNGAROTOXIN RECEPTOR; CATECHOL METHYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; HISTONE DEACETYLASE; KETAMINE; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOAMINE; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; PARVALBUMIN; PHENCYCLIDINE; REELIN; TRANSCRIPTION FACTOR AP 1;

CLINICAL FEATURE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; EPIGENETICS; GENETIC SUSCEPTIBILITY; HUMAN; MOLECULAR MECHANICS; NEGATIVE SYNDROME; NEUROPATHOLOGY; NONHUMAN; POSITIVE SYNDROME; PROTEIN SYNTHESIS INHIBITION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BRAIN; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; NERVE DEGENERATION; SCHIZOPHRENIA; SMALL MOLECULE LIBRARIES;

EID: 75149166426     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.12.004     Document Type: Review

References (40)

1. Stöber G., et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J. Biol. Psychiatry 10 (2009) 127-155
2. Crow T.J. How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am. J. Psychiatry 164 (2007) 13-21
3. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
4. Egan M.F., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6917-6922
5. Harrison P.J., and Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 60 (2006) 132-140
6. Millar J.K., et al. Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol. Psychiatry 6 (2001) 173-178
7. Halene T.B., and Siegel S.J. PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia?. Drug Discov. Today 12 (2007) 870-878
8. Hikida T., et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14501-14506
9. Millar J.K., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005) 1187-1191
10. Reneerkens O.A., et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl.) 202 (2009) 419-443
11. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch. Gen. Psychiatry 66 (2009) 128-133
12. Shifman S., et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 4 (2008) e28
13. Lewis D.A., et al. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
14. Durany N., and Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur. Psychiatry 19 (2004) 326-337
15. Cohen B.M., et al. Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs. Psychopharmacology (Berl.) 167 (2003) 403-410
16. Lee J., and Rajakumar N. Role of NR2B-containing N-methyl-d-aspartate receptors in haloperidol-induced c-Fos expression in the striatum and nucleus accumbens. Neuroscience 122 (2003) 739-745
17. Seillier A., et al. Bilateral lesions of the entorhinal cortex differentially modify haloperidol- and olanzapine-induced c-fos mRNA expression in the rat forebrain. Neuropharmacology 45 (2003) 190-200
18. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
19. Hansen H.H., et al. Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. J. Neurosci. Res. 85 (2007) 1810-1818
20. Thomsen M.S., et al. The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: differential effects in the juvenile and adult rat. Neuroscience 154 (2008) 741-753
21. Conn P.J., et al. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 30 (2009) 25-31
22. Fell M.J., et al. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326 (2008) 209-217
23. Lorrain D.S., et al. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117 (2003) 697-706
24. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
25. Siuciak J.A. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22 (2008) 983-993
26. Herdegen T., and Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res. Brain Res. Rev. 28 (1998) 370-490
27. Konradi C., and Heckers S. Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein. Neuroscience 65 (1995) 1051-1061
28. Emamian E.S., et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
29. Bitner R.S., et al. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 27 (2007) 10578-10587
30. Grande C., et al. Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol. Psychiatry 55 (2004) 457-463
31. Malhotra A.K., et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
32. Egerton A., et al. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology (Berl.) 198 (2008) 37-49
33. Thomsen M.S., et al. alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 56 (2009) 1001-1009
34. Thomsen, M.S. et al. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology, Curr. Pharm. Design, (in press)
35. Tsankova N., et al. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8 (2007) 355-367
36. Dong E., et al. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 13614-13619
37. Tremolizzo L., et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17095-17100
38. Akbarian S., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52 (1995) 258-266
39. Connor C.M., and Akbarian S. DNA methylation changes in schizophrenia and bipolar disorder. Epigenetics 3 (2008) 55-58
40. Li J., et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J. Neurochem. 90 (2004) 1117-1131